Consolidated segment reporting

Download (XLSX, 40 KB)
Consolidated segment reporting by business segment
Fresenius Medical Care Fresenius Kabi Fresenius Helios Fresenius Vamed Corporate Fresenius Group
€ in millions 20201 20192 Growth 20203 20194 Growth 2020 2019 Growth 2020 2019 Growth 20205 20196 Growth 2020 2019 Growth
Sales 17,859 17,477 2 % 6,976 6,919 1 % 9,818 9,234 6 % 2,068 2,206 -6 % -444 -427 -4 % 36,277 35,409 2 %
thereof contribution to consolidated sales 17,819 17,434 2 % 6,916 6,865 1 % 9,798 9,217 6 % 1,742 1,892 -8 % 2 1 100 % 36,277 35,409 2 %
thereof intercompany sales 40 43 -7 % 60 54 11 % 20 17 18 % 326 314 4 % -446 -428 -4 % 0 0  
contribution to consolidated sales 49 % 49 %   19 % 20 %   27 % 26 %   5 % 5 %   0 % 0 %   100 % 100 %  
EBITDA 4,090 3,913 5 % 1,490 1,573 -5 % 1,470 1,439 2 % 113 205 -45 % -63 -47 -34 % 7,100 7,083 0 %
Depreciation and amortization 1,591 1,557 2 % 395 368 7 % 445 414 7 % 84 71 18 % 200 42 -- 2,715 2,452 11 %
EBIT 2,499 2,356 6 % 1,095 1,205 -9 % 1,025 1,025 0 % 29 134 -78 % -263 -89 -196 % 4,385 4,631 -5 %
Net interest -368 -429 14 % -82 -83 1 % -180 -176 -2 % -20 -21 5 % -9 -10 10 % -659 -719 8 %
Income taxes -501 -452 -11 % -239 -276 13 % -171 -173 1 % -4 -28 86 % 12 46 -74 % -903 -883 -2 %
Net income attributable to
shareholders of Fresenius SE & Co. KGaA		 1,359 1,236 10 % 730 797 -8 % 666 664 0 % 2 83 -98 % -1,050 -897 -17 % 1,707 1,883 -9 %
                                     
Operating cash flow 4,233 2,567 65 % 1,143 1,028 11 % 1,149 733 57 % 78 -17 -- -54 -48 -13 % 6,549 4,263 54 %
Cash flow before acquisitions and dividends 3,197 1,454 120 % 450 312 44 % 609 256 138 % 2 -69 103 % -75 -123 39 % 4,183 1,830 129 %
                                     
Total assets 31,689 32,935 -4 % 13,591 13,797 -1 % 19,241 18,164 6 % 2,716 2,721 0 % -591 -611 3 % 66,646 67,006 -1 %
Debt 12,380 13,782 -10 % 4,181 4,375 -4 % 7,472 7,457 0 % 686 908 -24 % 1,194 736 62 % 25,913 27,258 -5 %
Other operating liabilities 6,192 5,185 19 % 3,225 3,207 1 % 2,585 2,084 24 % 933 1,034 -10 % 385 240 60 % 13,320 11,750 13 %
Capital expenditure, gross 1,052 1,125 -6 % 687 726 -5 % 541 482 12 % 95 56 70 % 23 74 -69 % 2,398 2,463 -3 %
Acquisitions, gross / investments 407 2,297 -82 % 31 86 -64 % 459 211 118 % 6 29 -79 % -1 0   902 2,623 -66 %
                                     
Research and development expenses 194 168 15 % 553 507 9 % 2 2 0 % 0 0   2 -32 106 % 751 645 16 %
Employees (per capita on balance sheet date) 133,129 128,300 4 % 40,519 39,627 2 % 116,952 106,377 10 % 19,414 18,592 4 % 1,255 1,238 1 % 311,269 294,134 6 %
                                     
Key figures                                    
EBITDA margin 22.9 % 22.4 %   21.4 % 22.7 %   15.0 % 15.6 %   5.5 % 9.3 %         19.7 %3 20.1 %8  
EBIT margin 14.0 % 13.5 %   15.7 % 17.4 %   10.4 % 11.1 %   1.4 % 6.1 %         12.7 %7 13.2 %8  
Depreciation and amortization in % of sales 8.9 % 8.9 %   5.7 % 5.3 %   4.5 % 4.5 %   4.1 % 3.2 %         7.5 % 6.9 %  
Operating cash flow in % of sales 23.7 % 14.7 %   16.4 % 14.9 %   11.7 % 7.9 %   3.8 % -0.8 %         18.1 % 12.0 %  
ROOA 8.2 % 7.6 %   9.2 % 10.5 %   5.7 % 6.1 %   1.3 % 7.0 %         7.3 %9 7.6 %10  
1 Before impairment of goodwill at FMC Latin America
2 Before transaction-related expenses, gain related to divestitures of Care Coordination activities and expenses associated with the cost optimization program
3 Before revaluations of biosimilars contingent purchase price liabilities
4 Before transaction-related expenses and revaluations of biosimilars contingent purchase price liabilities
5 After revaluations of biosimilars contingent purchase price liabilities and impairment of goodwill at FMC Latin America
6 After transaction-related expenses, revaluations of biosimilars contingent purchase price liabilities, gain related to divestitures of Care Coordination activities and expenses associated with the cost optimization program at FMC
7 Before revaluations of biosimilars contingent purchase price liabilities and impairment of goodwill at FMC Latin America
8 Before transaction-related expenses, revaluations of biosimilars contingent purchase price liabilities, gain related to divestitures of Care Coordination activities and expenses associated with the cost optimization program at FMC
9 The underlying pro forma EBIT does not include revaluations of biosimilars contingent purchase price liabilities and impairment of goodwill at FMC Latin America.
10 The underlying pro forma EBIT does not include transaction-related expenses, revaluations of biosimilars contingent purchase price liabilities, gain related to divestitures of Care Coordination activities and expenses associated with the cost optimization program at FMC.
The consolidated segment reporting by business segment is an integral part of the notes.
Download (XLSX, 36 KB)
Consolidated segment reporting by region
  Europe North America Asia-Pacific
€ in millions 2020 2019 Growth 2020 2019 Growth 2020 2019 Growth
Sales 15,813 15,178 4 % 14,801 14,543 2 % 3,705 3,732 -1 %
contribution to consolidated sales 44 % 43 %   41 % 41 %   10 % 11 %  
EBIT 883 1,143 -23 % 2,766 2,583 7 % 758 750 1 %
Depreciation and amortization 1,003 939 7 % 1,235 1,241 0 % 196 185 6 %
                   
Total assets 29,489 29,451 0 % 29,771 30,341 -2 % 5,018 5,055 -1 %
Capital expenditure, gross 1,253 1,183 6 % 861 1,027 -16 % 190 165 15 %
Acquisitions, gross / investments 199 259 -23 % 262 2,112 -88 % 28 43 -35 %
                   
Employees (per capita on balance sheet date) 174,835 165,862 5% 75,837 74,894 1 % 27,805 27,457 1 %
Download (XLSX, 36 KB)
Consolidated segment reporting by region
  Latin America Africa Fresenius Group
€ in millions 2020 2019 Growth 2020 2019 Growth 2020 2019 Growth
Sales 1,566 1,545 1 % 392 411 -5 % 36,277 35,409 2 %
contribution to consolidated sales 4 % 4 %   1 % 1 %   100 % 100 %  
EBIT -60 104 -158 % 38 51 -25 % 4,385 4,631 -5 %
Depreciation and amortization 270 74 -- 11 13 -15 % 2,715 2,452 11 %
                   
Total assets 2,056 1,868 10 % 312 291 7 % 66,646 67,006 -1 %
Capital expenditure, gross 86 77 12 % 8 11 -27 % 2,398 2,463 -3 %
Acquisitions, gross / investments 413 209 98 % 0 – -- 902 2,623 -66 %
                   
Employees (per capita on balance sheet date) 30,871 23,998 29 % 1,921 1,923 0 % 311,269 294,134 6 %

The consolidated segment reporting by region is an integral part of the notes.
Contact us

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-2294
pr-fre@fresenius.com

Visit us

Fresenius SE & Co. KGaA

Consolidated statement of changes in equity

Notes